Femasys announces uk regulatory approvals for femaseed® for female infertility treatment and two diagnostic devices

Atlanta, feb. 11, 2025 (globe newswire) -- femasys inc., (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the medicines & healthcare products regulatory agency (mhra) approvals for the femaseed® intratubal insemination product for female infertility treatment and two diagnostic devices, femvue® for tubal evaluation and femcerv® for cervical cancer detection. “this is another key milestone as we expand our reach to the uk following successful approval across europe for our innovative infertility and cancer detection products.
FEMY Ratings Summary
FEMY Quant Ranking